 "Cipla sells South African animal health biz to Ascendis for Rs 190 cr")
Drug manufacturer Cipla has sold its animal health business in South Africa to Ascendis Health for around Rs 190 crore as part of its strategy to streamline business and focus on core therapies.
Cipla's animal health portfolio, which exists in India and Africa, contributes less than one per cent to the company's consolidated revenue.
The drug maker said it had signed an agreement to divest its 100 per cent stake in two South African entities — Cipla Agrimed and Cipla Vet. The total consideration of the transaction would be 375 million South African Rand (around Rs 190 crore) with potential revision linked to the performance in financial year 2017 (within the price band of 250 million Rand and 500 million Rand).
Cipla's animal health division operates mainly in the farm animal segment and its main products include antimicrobials, endectocides, proton pump inhibitors, non-steroidal anti-inflammatory drugs, and supplements.
In a statement, Cipla South Africa CEO Paul Miller said that the company will increase its focus and efforts in advancing healthcare for all South Africans and will grow its portfolio of quality and affordable products and therapies.
The sale of the animal health business is in line with the company's strategy to cut down on non-core businesses and focus on key areas, including the respiratory segment. Its key markets include India, South Africa and the US.
Last year, it exited from several markets to reduce costs and complexities and also sold its stake in clinical stage biopharmaceutical company Chase Pharmaceuticals to Allergan.
From Cipla’s folio
From Cipla’s folio
- India, US and South Africa key markets for Cipla. Account for over 70 per cent of revenue
- Sale of animal health business is in line with the focus being on key therapy areas such as respiratory
- Cipla is exiting non-core businesses to reduce costs and complexities
- Animal health business contributes to less than one per cent of Cipla’s consolidated revenue
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%